Meeting
2023 ASCO Annual Meeting
Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base REMEMBER trial (WF97116).
Authors
Alayna E Ernster
Wake Forest University School of Medicine, Winston-Salem, NC
Alayna E Ernster , Emily Van Meter Dressler , W. Mark Brown , Glenn Jay Lesser , William P. Fusselman , Vinay K. Gudena , Lynne I. Wagner , Heidi D. Klepin , Edward G. Shaw , Steve R. Rapp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
NCT02822573
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12076)
DOI
10.1200/JCO.2023.41.16_suppl.12076
Abstract #
12076
Poster Bd #
444
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Quality of life and cognitive dysfunction in breast cancer survivors on a feasibility study of donepezil versus placebo.
First Author: Julia Lawrence
Poster
2015 ASCO Annual Meeting
Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors.
First Author: Abigail Gifford
Poster
2023 ASCO Quality Care Symposium
Assessing the effectiveness of a learning collaborative to build capacity for community-based cancer survivorship navigation.
First Author: Tamara Hamlish
Poster
2023 ASCO Annual Meeting
Effects of yoga vs placebo on inflammation among cancer survivors: A nationwide multicenter phase III randomized controlled trial (RCT).
First Author: Po-Ju Lin